Evidence map›Paper›PMID 27847338›Full record

SynthesisJournal of ethnopharmacology2016

A Chinese patent medicine, Shexiang Baoxin Pill, for Non-ST-elevation acute coronary syndromes: A systematic review.

Zhou Zhou, Weixing Shen, Lili Yu, Cong Xu, Qibiao Wu

2 registry-linked trialsAbstract readMeta-AnalysisSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Journal of ethnopharmacology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
7.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03072082 phase4unknown statusstarted 2017, after this paper: background citation

Study of Curative Effect Evaluation of DanLou Tablet on Coronary Artery Disease Not Amenable to Revascularization on the Basis of Western Medicine Therapy

Ran2017Enrolled440Registered outcomes6Posted comparisons0ConditionsCoronary Artery Disease(CAD)ArmsAspirin Enteric-coated Tablets, Atorvastatin calcium, Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet, Danlou Tablet, DanLou Tablet placebo
PMID 23173251PMID 20432394PMID 20531008PMID 20681275PMID 22019563PMID 23303884PMID 26142341PMID 27480425PMID 27491230other papers from this trial
Open the trial in the graph
NCT03072121 phase4unknown statusstarted 2017, after this paper: background citation

Study of Curative Effect Evaluation of Shexiang Baoxin Pill on Coronary Artery Disease Not Amenable to Revascularization on the Basis of Western Medicine Therapy

Ran2017Enrolled440Registered outcomes6Posted comparisons0ConditionsCoronary Artery Disease(CAD)ArmsAspirin Enteric-coated Tablets, Atorvastatin calcium, Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet, Isosorbide Mononitrate Tab 20 MG, Metoprolol Tartrate Tab 25 MG
PMID 20432394PMID 20531008PMID 20681275PMID 22019563PMID 23303884PMID 27480425other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 40 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Zhou ZhouState Key Laboratory of Quality Research in Chinese Medicines, Macau University of Science and Technology, Macau, PR China; Faculty of Chinese Medicine, Macau University of Science and Technology, Macau, PR China. Electronic address: zhouzhou0512@126.com.
Weixing ShenJiangsu Engineering Laboratory for Research and Industrialization of Empirical Formulae, Nanjing University of Chinese Medicine, Nanjing, PR China. Electronic address: shweixing@hotmail.com.
Lili YuState Key Laboratory of Quality Research in Chinese Medicines, Macau University of Science and Technology, Macau, PR China; Faculty of Chinese Medicine, Macau University of Science and Technology, Macau, PR China. Electronic address: llyu@must.edu.mo.
Cong XuFaculty of Chinese Medicine, Macau University of Science and Technology, Macau, PR China. Electronic address: 516053211@qq.com.
Qibiao WuState Key Laboratory of Quality Research in Chinese Medicines, Macau University of Science and Technology, Macau, PR China; Faculty of Chinese Medicine, Macau University of Science and Technology, Macau, PR China. Electronic address: qbwu@must.edu.mo.
Macau University of Science and Technology · MONanjing University of Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

ethnopharmacological relevanceShexiang Baoxin Pill (SXBXP) is a well-known Chinese patent medicine, widely used for Non-ST-elevation acute coronary syndromes (NSTE-ACS). It is composed of seven materia medicas or extracts (Moschus, Radix Ginseng, Calculus Bovis, Cortex Cinnamomi, Styrax, Venenum Bufonis and Borneolum Syntheticum). AIM OF THE STUDY: This study is aimed to systematically review the relevant randomised controlled trials (RCTs) to determine the efficacy and safety of SXBXP for long-term management of NSTE-ACS. MATERIALS AND

methodsA systematic review and meta-analysis were carried out in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. All randomised controlled trials (RCTs) comparing long-term Shexiang Baoxin Pill with conventional treatment, with outcome measures relating to efficacy and safety were selected. Primary clinical outcome was the risk of cardiovascular events, secondary outcomes were hospitalizations, angina symptoms, electrocardiogram (ECG) measurements, and adverse events.

resultsEleven RCTs recruiting 1389 patients were included, the overall risk of bias of the included trials is high and the quality poor. Compared with conventional treatment alone, long-term Shexiang Baoxin Pill plus conventional treatment might be more effective in lowering the risk of cardiovascular events (RR=0.36, 95% CI 0.26-0.49, <0.00001), hospitalizations (RR=0.38, 95% CI 0.21-0.67, P=0.0009), and improving angina symptoms (RR=1.19, 95% CI 1.13-1.26, P<0.00001), ECG measurements (RR=1.25, 95% CI 1.13-1.39, P<0.00001). Overall rate of adverse events was not elevated (P=0.43).

conclusionsFrom the available evidence, SXBXP added to conventional treatment may have beneficial effects on the long-term outcomes of NSTE-ACS, without serious adverse events. However, given the high risk of bias and low quality of the included trials, currently, there is no adequate evidence to draw any conclusions about its routine use. Large, methodologically-sound trials are needed to further assess its effects.

Indexed as

Acute Coronary SyndromeAnimalsDrugs, Chinese HerbalHumansMateria MedicaMedicine, Chinese TraditionalRandomized Controlled Trials as TopicRiskDrugs, Chinese HerbalMateria Medicashexiang baoxinAcute coronary syndromesBufalin (PubChem CID: 9547215)Cinnamic acid (PubChem CID: 444539)EfficacyGamabufotalin (PubChem CID: 259803)Ginsenoside Rb1 (PubChem CID: 118987129)Ginsenoside Rc (PubChem CID: 12855889)Ginsenoside Rg1 (PubChem CID: 441923)Meta-analysisMuscone (PubChem CID: 10947)Resibufogenin (PubChem CID: 10063)SafetyShexiang Baoxin PillSystematic review

Identifiers

PMID27847338
OpenAlexW2555462833

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.